Kymera Q2 FY26 net loss narrows to $61.21 million; revenue more than doubles to $65 million

• Kymera Therapeutics posted a net loss of $61.21 million, narrowing from $76.61 million a year earlier; loss per share improved to $0.62.
• Collaboration revenue more than doubled to $65 million from $11.48 million, driven by $45 million from Gilead’s KT-200 option exercise.
• R&D expenses climbed to $119.48 million from $78.39 million, due to higher STAT6, platform and discovery investment.
• Cash, cash equivalents and investments totaled $1.5 billion; management said this supports runway into 2029.
• KT-621 BROADEN2 Phase 2b AD enrollment finished nearly six months early, shifting topline data to year-end 2026; Phase 3 start targeted by mid-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kymera Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608050700PRIMZONEFULLFEED9803208) on August 05, 2026, and is solely responsible for the information contained therein.